Scope
Selected EAU 2026 recommendations for renal cell carcinoma, from renal-mass assessment and hereditary risk to nephron-sparing surgery, surveillance, adjuvant pembrolizumab and metastatic treatment. Treatment depends on stage, histology, recurrence or IMDC risk, renal function, frailty and patient goals.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Characterise and stage the renal mass
- Use multiphasic contrast-enhanced abdominal and chest CT for renal tumour diagnosis and staging. Omitting chest CT in incidentally detected cT1a disease is a weak recommendation because lung metastases are uncommon in that group. [1]
- Consider MRI for venous involvement, radiation reduction or avoidance of intravenous CT contrast. When contrast-enhanced CT is indeterminate, use MRI or contrast-enhanced ultrasound to further characterise renal masses or tumour thrombus. [1]
- Obtain renal tumour biopsy before ablation and before systemic treatment without previous pathology. Use coaxial core biopsy for solid tumours; do not biopsy a cystic mass unless imaging shows a significant solid component. Biopsy before active surveillance is selective. [1]
- Evaluate for hereditary RCC when age is 46 years or younger, tumours are bilateral or multifocal, relevant relatives have RCC or a pathogenic variant, or histology suggests hereditary disease. Refer suspected hereditary RCC to cancer genetics or a comprehensive care centre. [1]
Choose surgery or observation for localised disease
- Use TNM stage, WHO/ISUP grade, RCC subtype and prognostic models in localised and metastatic disease. Routine molecular markers are not recommended for prognosis. Screening older patients with a validated frailty score is a weak recommendation. [1]
- Offer surgery for cure of localised RCC and partial nephrectomy for T1 tumours. For T2 tumours with a solitary kidney or chronic kidney disease, consider partial nephrectomy when technically feasible; this latter recommendation is weak. [1]
- Do not remove the ipsilateral adrenal gland without clinical evidence of invasion, and do not routinely dissect lymph nodes in organ-confined disease. A microscopic positive surgical margin does not by itself warrant re-resection or radical nephrectomy; intensify follow-up instead. [1]
- Offer laparoscopic or robotic radical nephrectomy for T2 tumours or localised masses unsuitable for partial nephrectomy. Do not choose minimally invasive radical nephrectomy for a T1 tumour when partial nephrectomy is feasible, or use a minimally invasive approach that compromises outcomes. [1]
- Consider watchful waiting for highly frail, comorbid patients with reduced life expectancy. Active surveillance is a separate option for cT1a disease without an indication for immediate treatment when delayed intervention remains appropriate; discuss the limitations of its oncological evidence. [1]
- For cT1 lesions requiring treatment in patients unfit for surgery, consider ablation or stereotactic ablative radiotherapy. Obtain percutaneous biopsy before, rather than at, ablation and discuss evidence limitations. Routine radiofrequency ablation above 3 cm or cryoablation above 4 cm is discouraged. [1]
Locally advanced and adjuvant decisions
- Remove the renal tumour and venous thrombus in nonmetastatic disease with venous involvement. Discuss unresectable locally advanced RCC in a multidisciplinary team to define goals and choose biopsy, systemic therapy, deferred surgery or palliation. [1]
- Offer adjuvant pembrolizumab after restaging to clear-cell RCC meeting KEYNOTE-564 recurrence-risk criteria, preferably within 12–16 weeks of nephrectomy: pT2 grade 4 or sarcomatoid N0M0; pT3 any grade N0M0; pT4 N0M0; any pT with nodal involvement and M0; or no evidence of disease after oligometastatic resection within one year of nephrectomy. [1]
- Before adjuvant treatment, explain contradictory results across immune-checkpoint trials, possible overtreatment and immune-related adverse effects. Do not use neoadjuvant therapy outside a trial, and do not offer adjuvant sunitinib after resection of high-risk clear-cell RCC. [1]
- For recurrence during adjuvant pembrolizumab or within six months after completing its one-year course, the guideline weakly recommends VEGFR-targeted kinase treatment and advises against immune-checkpoint monotherapy or combinations in this setting. [1]
Metastatic local and systemic treatment
- Do not perform cytoreductive nephrectomy in IMDC/MSKCC poor-risk disease. For intermediate-risk patients with an asymptomatic synchronous primary tumour who require systemic therapy, start systemic treatment without immediate nephrectomy; consider delayed surgery if clinical benefit develops. [1]
- In selected metastatic disease with favourable factors and achievable complete resection, consider ablative treatment or metastasectomy for local symptoms. Obtain confirmatory axial imaging before metastasectomy to exclude rapid progression. Stereotactic radiotherapy can provide local control and symptom relief for relevant bone or brain metastases. [1]
- For first-line metastatic clear-cell RCC with IMDC intermediate or poor risk, offer one of nivolumab–ipilimumab, pembrolizumab–axitinib, pembrolizumab–lenvatinib or nivolumab–cabozantinib. These combinations are alternatives, not a combined multi-drug regimen. [1]
- For IMDC favourable-risk metastatic clear-cell RCC, the guideline weakly recommends pembrolizumab plus axitinib, lenvatinib plus pembrolizumab, nivolumab plus cabozantinib, nivolumab plus ipilimumab or sunitinib or pazopanib as options. For advanced clear-cell disease with sarcomatoid features, offer checkpoint combination therapy. [1]
- After progression on a first-line checkpoint combination, use a VEGF-targeted kinase inhibitor such as cabozantinib. Nivolumab or cabozantinib are options after first-line VEGF-targeted therapy alone. Rechallenge after stopping checkpoint treatment for toxicity requires expert multidisciplinary guidance. [1]
- For metastatic papillary RCC, consider cabozantinib, or lenvatinib–pembrolizumab or nivolumab–cabozantinib; these are weak recommendations, with the combination evidence coming from small single-arm trials. Do not automatically extrapolate clear-cell treatment evidence to other histologies. [1]
Risk-adapted follow-up and support
- Base follow-up after localised RCC treatment on recurrence risk using validated subtype-specific models, and intensify surveillance after nephron-sparing surgery with a positive margin. Consider curtailing follow-up when competing mortality risk is twice the risk of RCC recurrence. [1]
- Offer psychological evaluation to identify distress, depression or anxiety. Seek nephrology input for pre-existing or treatment-induced chronic kidney disease or comorbidities that threaten renal function; these supportive recommendations are weak. [1]
Limitations and use
- This summary covers selected decision points, not complete drug schedules, toxicity management, hereditary syndrome protocols, rare-histology treatment or imaging follow-up calendars.
- Systemic choices require specialist assessment, current product information and Indian availability; European guideline inclusion does not establish local approval.
- Several surveillance, ablative, non-clear-cell and sequencing recommendations are weak and should be discussed with their evidence limitations.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Renal cell carcinoma
Selected recommendation material consulted
Publication details
- Issuing organisation
- EAU
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- Europe
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.